Fan L, Wu Y, Wei J, et al. Global, regional, and national time trends in incidence for migraine, from 1990 to 2019: an age-period-cohort analysis for the GBD 2019. J Headache Pain. 2023;24(1):79.
Bonafede M, Sapra S, Shah N, et al. Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache. 2018;58(5):700-714.
Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care. 2019;25(suppl 2):S23-S34.
Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache. 2018;58(4):496-505.
Mayans L, Walling A. Acute migraine headache: treatment strategies. Am Fam Physician. 2018;97(4):243-251.
Viera AJ, Antono B. Acute headache in adults: a diagnostic approach. Am Fam Physician. 2022;106(3):260-268.
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.
Gilmore B, Michael M. Treatment of acute migraine headache. Am Fam Physician. 2011;83(3):271-280.
Detsky ME, McDonald DR, Baerlocher MO, et al. Does this patient with headache have a migraine or need neuroimaging? JAMA. 2006;296(10):1274-1283.
Ebell MH. Diagnosis of migraine headache. Am Fam Physician. 2006;74(12):2087-2088.
Martin VT, Feoktistov A, Solomon GD. A rational approach to migraine diagnosis and management in primary care. Ann Med. 2021;53(1):1979-1990.
US Department of Veterans Affairs and US Department of Defense. Management of headache. Updated November 8, 2024. Accessed February 5, 2025. https://www.healthquality.va.gov/guidelines/Pain/headache/
Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clin. 2019;37(4):631-649.
Marmura MJ. Triggers, protectors, and predictors in episodic migraine. Curr Pain Headache Rep. 2018;22(12):81.
Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021-1039.
Becker WJ. Acute migraine treatment in adults. Headache. 2015;55(6):778-793.
Lipton RB, Stewart WF, Stone AM, et al.; Disability in Strategies of Care Study Group. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: a randomized trial. JAMA. 2000;284(20):2599-2605.
Lipton RB, Stewart WF, Sawyer J, et al. Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache. 2001;41(9):854-861.
Steiner TJ, Stovner LJ, Vos T, et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19(1):17.
Lipton RB, Fanning KM, Serrano D, et al. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015;84(7):688-695.
Halker Singh RB, VanderPluym JH, Morrow AS, et al. Acute treatments for episodic migraine. Comparative effectiveness review no. 239. Agency for Healthcare Research and Quality; December 2020. Accessed April 12, 2024. https://www.ncbi.nlm.nih.gov/books/NBK566246/
VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute treatments for episodic migraine in adults: a systematic review and meta-analysis. JAMA. 2021;325(23):2357-2369.
Khan ZZ, Ahmed U, Shahzad F, et al. Safety and efficacy of zavegepant in treating migraine: a systematic review. Cureus. 2023;15(7):e41991.
Lipton RB, Croop R, Stock DA, et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 2023;22(3):209-217.
Ubrelvy (ubrogepant) [package insert]. Allergan, Inc.; 2019. Accessed March 20, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf
Nurtec ODT (rimegepant) [package insert]. Biohaven Pharmaceuticals, Inc.; 2021. Accessed March 20, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212728s006lbl.pdf
Vila-Pueyo M. Targeted 5-HT1F therapies for migraine. Neurotherapeutics. 2018;15(2):291-303.
Reyvow (lasmiditan) [package insert]. Eli Lilly and Company; 2022. Accessed March 20, 2024. https://pi.lilly.com/us/reyvow-uspi.pdf
Krege JH, Rizzoli PB, Liffick E, et al. Safety findings from phase 3 lasmiditan studies for acute treatment of migraine: results from SAMURAI and SPARTAN. Cephalalgia. 2019;39(8):957-966.
Lipton RB, Munjal S, Dodick DW, et al. Acute treatment of migraine with celecoxib oral solution: results of a randomized, placebo-controlled clinical trial. J Pain Res. 2021;14:549-560.
Messlinger K. The big CGRP flood - sources, sinks and signalling sites in the trigeminovascular system. J Headache Pain. 2018;19(1):22.
Huang T, Xu Y, Chen Y, et al. Efficacy and safety of calcitonin gene–related peptide antagonists in migraine treatment: a meta-analysis. Brain Behav. 2022;12(4):e2542.
Yang Y, Chen M, Sun Y, et al. Safety and efficacy of ubrogepant for the acute treatment of episodic migraine: a meta-analysis of randomized clinical trials. CNS Drugs. 2020;34(5):463-471.
Gao B, Yang Y, Wang Z, et al. Efficacy and safety of rimegepant for the acute treatment of migraine: evidence from randomized controlled trials. Front Pharmacol. 2020;10:1577.
Charles AC, Digre KB, Goadsby PJ, et al.; American Headache Society. Calcitonin gene–related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024;64(4):333-341.
Zavzpret (zavegepant) [package insert]. Pfizer Labs; 2023. Accessed March 20, 2024. www.accessdata.fda.gov/drugsatfda_docs/label/2023/216386s000lbl.pdf
Marshall C, Torro J. Lasmiditan (Reyvow) for the treatment of acute migraine. Am Fam Physician. 2020;102(12):756-757.
Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache. 2006;46(suppl 4):S171-S181.
Loder E, Weizenbaum E, Frishberg B, et al.; American Headache Society Choosing Wisely Task Force. Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question. Headache. 2013;53(10):1651-1659.
Iljazi A, Chua A, Rich-Fiondella R, et al. Unrecognized challenges of treating status migrainosus: an observational study. Cephalalgia. 2020;40(8):818-827.
Kiarashi J, Jion Y, Giglio B, et al. Elective hospitalizations for intractable headache: outcomes and response predictors. Neurol Clin Pract. 2021;11(3):188-193.
Liu Y, Wang Y, Mi C, et al. Efficacy of acupuncture-related therapy for migraine: a systematic review and network meta-analysis. J Pain Res. 2024;17:1107-1132.
Ni X, Dong L, Tian T, et al. Acupuncture versus various control treatments in the treatment of migraine: a review of randomized controlled trials from the past 10 years. J Pain Res. 2020;13:2033-2064.
Ou MQ, Fan WH, Sun FR, et al. A systematic review and meta-analysis of the therapeutic effect of acupuncture on migraine. Front Neurol. 2020;11:596.
Linde K, Allais G, Brinkhaus B, et al. Acupuncture for the prevention of episodic migraine. Cochrane Database Syst Rev. 2016(6):CD001218.
Chowdhury D, Datta D, Mundra A. Role of greater occipital nerve block in headache disorders: a narrative review. Neurol India. 2021;69(suppl):S228-S256.
Cromb D, Grigoratos D. Acute treatment of migraine in children and adolescents: review of the American Academy of Neurology practice guideline update. Arch Dis Child Educ Pract Ed. 2021;106(6):358-361.
Tepper DE. Migraine in children. Headache. 2017;57(6):1021-1022.
Martin VT, Ahmed Z, Hochstetler HM, et al. Tolerability and safety of lasmiditan treatment in elderly patients with migraine: post hoc analyses from randomized studies. Clin Ther. 2021;43(6):1066-1078.
Headaches in pregnancy and postpartum: ACOG clinical practice guideline No. 3. Obstet Gynecol. 2022;139(5):944-972.
Saldanha IJ, Roth JL, Chen KK, et al. Management of primary headaches in pregnancy. Comparative effectiveness review no. 234. Agency for Healthcare Research and Quality; November 2020. Accessed April 11, 2024. https://www.ncbi.nlm.nih.gov/books/NBK564853/
Aukerman G, Knutson D, Miser WF. Management of the acute migraine headache. Am Fam Physician. 2002;66(11):2123-2131.